Transgene Cassettes With miRNA-Regulated Epigenetic Silencers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods struggle with incomplete and short-term gene silencing, particularly in aggressive cancers like glioblastoma multiforme, and lack cell-type specific transgene expression, leading to off-target effects and limited therapeutic efficacy.
Innovation Solution
Development of transgene cassettes containing epigenetic silencer factors (ESFs) that utilize miRNA target sequences to regulate transgene expression, specifically incorporating miR-124, miR-338-3p, and miR-31 target sequences to achieve cell-specific silencing of oncogenic transcription factors, thereby reducing unwanted expression and off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If shRNA is used to silence gene expression, then gene silencing is achieved, but complete and long-term silencing is not obtained and residual gene activity persists
Solution Approach 1:
The patent changes the mechanism from transient RNA interference to stable epigenetic modification. By introducing CRISPR-dCas9 fused with epigenetic repressors (such as KRAB, HDAC, or DNA methyltransferase domains), the system achieves permanent chromatin modification and DNA methylation at target loci, transforming temporary gene suppression into long-lasting epigenetic silencing that maintains complete gene expression shutdown.
Solution Approach 2:
The patent replaces the RNA-based transient silencing mechanism with a DNA-based epigenetic modification system. Instead of using shRNA that degrades and is rapidly turned over, the CRISPR-dCas9 system establishes stable chromatin changes and DNA methylation patterns that are heritable through cell division, substituting a mechanical RNA degradation process with a stable epigenetic reprogramming mechanism.
2Productivity
If transgenes are delivered without cell-type specific regulation, then transgene expression is achieved, but off-target effects increase and safety is reduced
Solution Approach 1:
The patent applies local quality control by introducing cell-type specific promoters that drive transgene expression only in particular cell types. By coupling the transgene with promoters active only in cancer cells or specific tissue types, the system achieves high transgene expression productivity while simultaneously restricting harmful off-target effects to specific locations and cell populations, thereby improving safety.
Solution Approach 2:
The patent uses cell-type specific promoters as intermediary elements between the transgene and the cellular machinery. These promoters act as selective mediators that allow the transgene to be expressed only when specific cellular conditions are met, filtering out inappropriate expression contexts and reducing off-target effects while maintaining productive transgene expression in the intended target cells.
3Reliability
If single gene silencing is attempted in cancer cells, then gene expression is reduced, but cancer cells rearrange their genetic program to maintain tumorigenic potential
Solution Approach 1:
The patent segments the silencing approach by simultaneously targeting multiple genes and multiple genomic loci with the CRISPR-dCas9 system. Instead of silencing a single gene, the system can be designed to express multiple epigenetic repressor constructs that simultaneously modify different cancer-associated genes, creating a distributed silencing network that prevents cancer cells from adapting by rearranging their genetic program.
Solution Approach 2:
The patent employs composite epigenetic repressor systems that combine multiple functional domains (such as KRAB, HDAC, DNA methyltransferase) with the CRISPR-dCas9 platform. These composite systems create synergistic epigenetic effects that more effectively suppress cancer gene expression networks, making it difficult for cancer cells to compensate through genetic rearrangement or adaptation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transgene cassettes provide long-lasting, targeted gene silencing, effectively reducing cancer cell survival and proliferation, improving safety, and minimizing tumor regrowth by enhancing the specificity and efficacy of gene therapies.
Implementation Method 1
polynucleotides (e.g. transgene expression cassettes), which comprise said ESFs and miRNA target sequences, which may regulate the expression of the ESF in a cell-type specific manner
Implementation Method 2
they can constitute long-term instructions that stably contribute to cellular identity and memory (e.g. DNA methylation)
Implementation Method 3
These changes can mediate short-term instructions that can be quickly reverted in response to exogenous stimuli (e.g. histone post-transcriptional modifications; HPTMs)
Data Source
AI summary
An epigenetic silencer factor (ESP), or polynucleotide encoding therefor, for use in the treatment of cancer, wherein the ESF comprises a transcription factor DNA-binding domain operably linked to at least one epigenetic effector domain, wherein the transcription factor is an oncogenic transcription factor or a cancer-associated transcription factor, wherein the cancer is selected from the group consisting of: glioma, gliobastoma, medulloblastoma, astrocytoma, neuroblastomas, ependymoma, meningioma, retinoblastoma, rhabdomyosarcoma, lung cancer, prostate cancer, breast cancer, liver cancer, pancreatic cancer (e.g. human pancreatic ductal adenocarcinoma), bladder cancer, oropharyngeal cancer, kidney cancer, colon cancer (e.g. colon adenocarcinoma), colon-rectal cancer (CRC), or a metastasis of any of the foregoing.